Redeye believes Lagercrantz continued its stable trend and ended fiscal year 2024/2025 in a solid fashion. Organic growth kept improving sequentially, while the company posted decent execution on the M&A front. We nudge up our fair value range and believe Lagercrantz will deliver solid profit growth, aligning with its target of c15% annual profit expansion.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/